Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.62 |
| ▸ | MAOB | P27338 | 2/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.57 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.50 |
| ▸ | CFD | P00746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27247548 | 0.89 | ALOX5 (0.55) | LOXL2MAOBMAOAKDM4EALDH1A1 | |
| SCHEMBL5093641 | 0.86 | CYP1A2 (0.65) | LOXL2MAOBMAOAKDM4EALDH1A1 | |
| SCHEMBL15141030 | 0.82 | SRD5A2 (0.68) | MAOBMAOAKDM4EALDH1A1CYP1A2 | |
| SCHEMBL8187385 | 0.82 | MAOA (0.59) | LOXL2MAOBMAOAKDM4EALDH1A1 | |
| SCHEMBL852375 | 0.81 | KDM4E (0.67) | MAOBMAOAKDM4EALDH1A1CYP1A2 | |
| SCHEMBL19211169 | 0.81 | MAOA (0.58) | MAOBMAOAKDM4EALDH1A1CYP1A2 | |
| SCHEMBL6990842 | 0.80 | MAOB (0.57) | LOXL2MAOBMAOAKDM4EALDH1A1 | |
| SCHEMBL5123477 | 0.79 | KDM4E (0.64) | MAOBMAOAKDM4EALDH1A1CYP1A2 | |
| SCHEMBL28798233 | 0.79 | KDM4E (0.64) | MAOBMAOAKDM4EALDH1A1CYP1A2 | |
| SCHEMBL5097564 | 0.79 | ALDH1A1 (0.64) | MAOBMAOAKDM4EALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0754455-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON AMINOMETHYLINDOLES AND THEIR THERAPEUTICAL APPLICATION AS NEUROPROTECTORS IN PARKINSON AND ALZHEIMER DISEASES | CONSEJO SUPERIOR INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 1997-01-22 | — | — | EP | claimed |
| US-20240124404-A1 | COMPOSITION FOR TREATING DISEASES RELATED TO ADVANCED GLYCATION END PRODUCTS COMPRISING INDOLE DERIVATIVE | METACEN THERAPEUTICS (KR) | 2024-04-18 | — | — | US | disclosed |
| US-20240124399-A1 | NOVEL INDOLE DERIVATIVE, AND USE THEREOF FOR TREATING DISEASES RELATED TO ADVANCED GLYCATION END PRODUCTS | METACEN THERAPEUTICS (KR) | 2024-04-18 | — | — | US | disclosed |
| EP-4353710-A1 | NOVEL INDOLE DERIVATIVE, AND USE THEREOF FOR TREATING DISEASES RELATED TO ADVANCED GLYCATION END PRODUCTS | Metacen Therapeutics (KR) | 2024-04-17 | — | — | EP | disclosed |
| EP-4353227-A1 | COMPOSITION INCLUDING INDOLE DERIVATIVE FOR PREVENTION OF ADVANCED GLYCATION END PRODUCT-RELATED DISEASE | Metacen Therapeutics (KR) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022260491-A1 | NOVEL INDOLE DERIVATIVE, AND USE THEREOF FOR TREATING DISEASES RELATED TO ADVANCED GLYCATION END PRODUCTS | 주식회사 메타센테라퓨틱스 | 2022-12-15 | — | — | WO | disclosed |
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110144177-A1 | Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents | COLUCID PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
| EP-2314571-A2 | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | CoLucid Pharmaceuticals, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| US-7897639-B2 | Amine group that, upon hydrolysis, becomes a component of a pharmacologically active agent for treatment of nervous system disordres | COLUCID PHARMACEUTICALS, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008097546-A2 | COMPOUNDS THAT INHIBIT CHOLINESTERASE | COLUCID PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| US-20070275959-A1 | Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents | SENTION, INC. | 2007-11-29 | — | — | US | disclosed |
| EP-1689704-A2 | CARBAMOYL ESTERS THAT INHIBIT CHOLINESTERASE AND RELEASE PHARMACOLOGICALLY ACTIVE AGENTS | CoLucid Pharmaceuticals, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005042475-A2 | CARBAMOYL ESTERS THAT INHIBIT CHOLINESTERASE AND RELEASE PHARMACOLOGICALLY ACTIVE AGENTS | SENTION, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20050096387-A1 | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | SENTION, INC. (US) | 2005-05-05 | — | — | US | disclosed |
| EP-0754455-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON AMINOMETHYLINDOLES AND THEIR THERAPEUTICAL APPLICATION AS NEUROPROTECTORS IN PARKINSON AND ALZHEIMER DISEASES | CONSEJO SUPERIOR INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 1997-01-22 | — | — | EP | disclosed |
| EP-0754455-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON AMINOMETHYLINDOLES AND THEIR THERAPEUTICAL APPLICATION AS NEUROPROTECTORS IN PARKINSON AND ALZHEIMER DISEASES | CONSEJO SUPERIOR INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 1997-01-22 | — | — | EP | disclosed |
| WO-1996024349-B1 | PHARMACEUTICAL COMPOSITIONS BASED ON AMINOMETHYLINDOLES AND THEIR THERAPEUTICAL APPLICATION AS NEUROPROTECTORS IN PARKINSON AND ALZHEIMER DISEASES | — | 1996-09-19 | — | — | WO | disclosed |
| WO-1996024349-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON AMINOMETHYLINDOLES AND THEIR THERAPEUTICAL APPLICATION AS NEUROPROTECTORS IN PARKINSON AND ALZHEIMER DISEASES | CONSEJO SUPERIOR INVESTIGACIONES CIENTIFICAS (ES) | 1996-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124404-A1 | COMPOSITION FOR TREATING DISEASES RELATED TO ADVANCED GLYCATION END PRODUCTS COMPRISING INDOLE DERIVATIVE | AGER, IDO1, IAPP | LOXL2 576/4885MAOB 231/4885MAOA 135/4885 |
| US-20110144177-A1 | Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents | ACHE, BCHE, CHAT | LOXL2 3454/4885MAOB 324/4885MAOA 184/4885 |
| US-20070275959-A1 | Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents | ACHE, BCHE, CHAT | LOXL2 3583/4885MAOB 279/4885MAOA 162/4885 |
| US-20240124399-A1 | NOVEL INDOLE DERIVATIVE, AND USE THEREOF FOR TREATING DISEASES RELATED TO ADVANCED GLYCATION END PRODUCTS | AGER, IDO1, IDO2 | LOXL2 370/4885MAOB 124/4885MAOA 54/4885 |
| US-20050096387-A1 | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | ACHE, BCHE, CHAT | LOXL2 3454/4885MAOB 324/4885MAOA 184/4885 |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | ACHE, BCHE, CHAT | LOXL2 3238/4885MAOB 41/4885MAOA 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.